Sign In
Buy ABT
$100.79
+0.200 (+0.199%)
At Close: Jul 23, 2026
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
02:18pm, Friday, 10'th Jul 2026
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
10:31am, Thursday, 09'th Jul 2026
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
05:03pm, Wednesday, 08'th Jul 2026
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized fo
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
05:30pm, Tuesday, 07'th Jul 2026
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
02:00pm, Tuesday, 07'th Jul 2026
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 06'th Jul 2026
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio
08:30am, Monday, 06'th Jul 2026
These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
04:00pm, Friday, 03'rd Jul 2026
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth can
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
08:18am, Thursday, 02'nd Jul 2026
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify thei
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
04:08pm, Wednesday, 01'st Jul 2026
Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines. Intuitive Surgical maintains a dominant position in robotic-assist
Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable i
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
07:02am, Wednesday, 01'st Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Monday, 29'th Jun 2026
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
04:43pm, Monday, 29'th Jun 2026
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be
3 No-Brainer Dividend Stocks to Buy Right Now
11:43am, Monday, 29'th Jun 2026
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
